FIELD: medicine.
SUBSTANCE: correcting cognitive disorders in the patients suffering arterial hypertension accompanying type 2 diabetes mellitus is ensured by combining a standard drug therapy with administering the preparation Kudesan 60 mg a day throughout two months.
EFFECT: administering Kudesan in the above dose and regimen provides the effective correction of cognitive disorders in the above group of patients in a combination with improving the cardiovascular function and metabolic processes.
2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CORRECTING INCREASED LEVELS OF ANXIETY AND DEPRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2014 |
|
RU2554806C1 |
| METHOD FOR CORRECTION OF LIPOPEROXIDATION ACCOMPANYING HYPOLIPIDEMIC THERAPY OF PATIENTS WITH METABOLIC SYNDROME | 2011 |
|
RU2458687C1 |
| METHOD FOR DETERMINING RISK OF CORONARY ARTERY ATHEROSCLEROSIS IN PATIENTS SUFFERING FROM DIABETES MELLITUS ACCOMPANIED BY CARDIOVASCULAR DISORDERS | 2013 |
|
RU2532521C1 |
| METHOD OF ASSESSING AGE-RELATED CHANGES OF HUMAN CARDIOVASCULAR SYSTEM | 2012 |
|
RU2485886C1 |
| METHOD DETERMINING TACTICS OF CARRYING OUT OF MEDICAL ACTIONS AT PATIENTS WITH METABOLIC SYNDROME AGAINST ARTERIAL HYPERTENSIA | 2007 |
|
RU2337612C1 |
| METHOD FOR MONITORING INDIVIDUALS WITH RISK OF EARLY ATHEROSCLEROSIS AND SUFFERING FROM TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2533836C1 |
| METHOD FOR SELECTING PATIENTS WITH DIABETES MELLITUS OF TYPE 2 IN RISK GROUP OF DEVELOPING ENDOTHELIAL DYSFUNCTION | 2015 |
|
RU2607187C1 |
| METHOD FOR CLINICAL PREDICTION OF PROBABILITY OF SUFFERED SILENT STROKE IN PATIENTS WITH ARTERIAL HYPERTENSION | 2013 |
|
RU2534865C1 |
| METHOD FOR PREDICTING ISCHEMIC CARDIAC DISEASE IN PATIENTS WITH ARTERIAL HYPERTENSION | 2006 |
|
RU2316995C1 |
| METHOD OF TREATING PATIENTS WITH ISCHEMIC HEART DISEASE | 2010 |
|
RU2428978C1 |
